Treating disorders associated with aberrant adrenocortical cell behavior

A method for treating a disorder associated with aberrant adrenocortical cell behavior in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an agent which:

• (a) exhibits an IC50 value against human ACAT1 (huACAT1) of less than 10 μM;
• and (b) disrupts cholesterol homeostasis in adrenocortical cells;
• wherein the agent is not N-(2,6-bis(1-methylethyl)-phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea or a salt thereof.

A method for treating a disorder associated with aberrant adrenocortical cell behavior in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an agent which:

• (a) exhibits an IC50 value against huACAT1 of less than 10 μM;
• and (b) reduces steroid biosynthesis in adrenocortical cells, and wherein the agent is not N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)-cyclopentyl)-methyl)urea or a salt thereof.

A method for treating a disorder associated with aberrant adrenocortical cell behavior in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an agent which:

• (a) exhibits an IC50 value against huACAT1 of less than 10 μM;
• and (b) reduces mitochondrial function in adrenocortical cells, and wherein the agent is not N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)-cyclopentyl)-methyl)urea or a salt thereof.

A method for treating a disorder associated with aberrant adrenocortical cell behavior in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an agent which:

• (a) exhibits an IC50 value against huACAT1 of less than 10 μM;
• and (b) is preferentially bound by low-density lipoprotein (LDL), and wherein the agent is not N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)-cyclopentyl)-methyl)urea or a salt thereof.